Stryker (NYSE:SYK) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Stryker (NYSE:SYK) from a hold rating to a buy rating in a report released on Saturday morning.

SYK has been the topic of a number of other research reports. Truist Financial dropped their target price on Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday. Wells Fargo & Company dropped their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $401.43.

Stryker Trading Down 6.3%

Shares of Stryker stock opened at $295.43 on Friday. Stryker has a 52 week low of $294.55 and a 52 week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock has a 50 day moving average price of $345.67 and a two-hundred day moving average price of $356.89. The stock has a market capitalization of $113.15 billion, a PE ratio of 34.19, a price-to-earnings-growth ratio of 1.72 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.74%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker will post 14.89 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

A number of hedge funds have recently bought and sold shares of SYK. Czech National Bank increased its position in Stryker by 3.9% in the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after buying an additional 3,366 shares during the last quarter. Davis R M Inc. increased its position in Stryker by 1.8% in the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after buying an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC purchased a new stake in Stryker in the third quarter worth $1,216,000. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker in the third quarter worth $27,952,000. Finally, Daymark Wealth Partners LLC increased its position in Stryker by 436.0% in the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after buying an additional 37,307 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY?2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer?term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near?term upside expectations and add selling pressure. Article Title

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.